AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22206862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' occupational social class at birth
Number of subjects: 1559
Study 22206862 — intervention group
Group type: COMPARATOR
Intervention: UKALL XI trial participants
Number of subjects: 1559
Study 22206862 — intervention group
Group type: COMPARATOR
Intervention: Sex and age at diagnosis
Number of subjects: 1559
Study 21353111 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone (10 mg/kg)
Number of subjects: 60
Study 21353111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen combined with acetaminophen (10 mg/kg ibuprofen + 15 mg/kg acetaminophen)
Number of subjects: 60
Study 21353111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen followed by acetaminophen (10 mg/kg ibuprofen followed by 15 mg/kg acetaminophen 3 hours later)
Number of subjects: 60
Study 18443566 — intervention group
Group type: EXPERIMENTAL
Intervention: wrist‐HBP (Omron R7 with position sensor)
Number of subjects: 79
Study 18443566 — intervention group
Group type: COMPARATOR
Intervention: arm‐HBP (Omron 705IT)
Number of subjects: 79
Study 18443566 — intervention group
Group type: COMPARATOR
Intervention: ambulatory BP (ABP, SpaceLabs)
Number of subjects: 79
Study 18443566 — intervention group
Group type: EXPERIMENTAL
Intervention: wrist‐arm HBP difference
Number of subjects: 79
Study 16754526 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intervention (one visit with asthma self‐management education and provision of inhaled budesonide)
Number of subjects: 0
Study 16754526 — intervention group
Group type: COMPARATOR
Intervention: Regular asthma care manager follow‐up
Number of subjects: 0
Study 14530005 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting plus transmyocardial laser revascularization
Number of subjects: 20
Study 14530005 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 20
Study 11168192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique lateral cephalometric radiography (OLCR)
Number of subjects: 16
Study 11168192 — intervention group
Group type: COMPARATOR
Intervention: Standard horizontal X-ray beam direction
Number of subjects: 16
Study 11168192 — intervention group
Group type: COMPARATOR
Intervention: Optimal horizontal X-ray beam direction
Number of subjects: 16
Study 9289706 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with disturbances in carbohydrate and lipid metabolism
Number of subjects: 51
Study 9289706 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with disturbance in lipid metabolism
Number of subjects: 51
Study 9289706 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with no symptoms of metabolic diseases
Number of subjects: 51
Study 9289706 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls before fat rich meal
Number of subjects: 51
Study 9289706 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls after fat rich meal
Number of subjects: 51
Study 1475671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene motivation tool (Parograph)
Number of subjects: 100
Study 1475671 — intervention group
Group type: COMPARATOR
Intervention: Classic clinical methods (brush-techniques)
Number of subjects: 100
Study 6228196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (13‐cis‐retinoic acid) for four months
Number of subjects: 20
Study 31273316 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the percentage of the sarcomatoid component
Number of subjects: 54
Study 31273316 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the transitional pattern
Number of subjects: 54
Study 30239767 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG vaccination
Number of subjects: 6583
Study 28480343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted prone with 'Bernoulli maneuver' (B)
Number of subjects: 67
Study 28480343 — intervention group
Group type: COMPARATOR
Intervention: Standard prone (C)
Number of subjects: 67
Study 28480343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C and B)
Number of subjects: 67
Study 27302514 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon radiation therapy (XRT)
Number of subjects: 35
Study 24899076 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention plus referral list
Number of subjects: 403
Study 24899076 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus referral list
Number of subjects: 403
Study 21761149 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 19
Study 21761149 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 19
Study 19653744 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of numerically smaller digit first
Number of subjects: 6
Study 19653744 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of letters pairs (e.g., A-Z)
Number of subjects: 6
Study 19653744 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of mixed digit-letter pairs (e.g., 1-Z)
Number of subjects: 6
Study 17326881 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 microg intravaginally every 3 h, max 200 microg)
Number of subjects: 100
Study 17326881 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg PGE(2) gel intracervically every 6 h, max three doses in 24 h)
Number of subjects: 100
Study 17326881 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 100
Study 17326881 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 100
Study 15871365 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride (Ganaton) 50 mg three times daily for 2 weeks
Number of subjects: 60
Study 15871365 — intervention group
Group type: COMPARATOR
Intervention: Mosapride citrate 5 mg three times daily for 2 weeks
Number of subjects: 60
Study 11361191 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive coping style of resting
Number of subjects: 190
Study 11361191 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coping style of transforming pain
Number of subjects: 190
Study 11361191 — intervention group
Group type: COMPARATOR
Intervention: Coping styles (both active and passive)
Number of subjects: 190
Study 9531075 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin, 70 mg i.m. qd for the first month and every other day thereafter
Number of subjects: 634
Study 9531075 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term antimicrobial chemoprophylaxis with pefloxacin (800 mg i.v. qd for the first 4 days) and polychemotherapy with teicoplanin (800 mg i.v. qd) and netilmicin (300 mg i.m. qd)
Number of subjects: 634
Study 9531075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 634
Study 9531075 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 634
Study 7976582 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 0
Study 7976582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2684316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogens
Number of subjects: 0
Study 2684316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30741747 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% PPO trial
Number of subjects: 11
Study 30741747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive bouts (84% ± 2% PPO)
Number of subjects: 11
Study 30741747 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE during exercise
Number of subjects: 11
Study 27492276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Number of subjects: 90
Study 27492276 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (sham ischemic compression)
Number of subjects: 90
Study 27492276 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 25511214 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl added to 0.5% bupivacaine
Number of subjects: 64
Study 25511214 — intervention group
Group type: COMPARATOR
Intervention: Normal saline mixed with 10 ml of 0.5% bupivacaine
Number of subjects: 64
Study 23281974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 40
Study 20634018 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ITD-7
Number of subjects: 81
Study 20634018 — intervention group
Group type: COMPARATOR
Intervention: Sham ITD-7
Number of subjects: 81
Study 20634018 — intervention group
Group type: EXPERIMENTAL
Intervention: ITD-7 in prehospital setting
Number of subjects: 81
Study 19487509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1226
Study 19487509 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1226
Study 19487509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1226
Study 18072125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of droperidol (DROP) IM
Number of subjects: 20
Study 18072125 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 20
Study 14715050 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (specific drugs not mentioned)
Number of subjects: 0
Study 14715050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency antipsychotics coadministered with inhibitors such as clarithromycin
Number of subjects: 0
Study 14715050 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for adverse cardiovascular events
Number of subjects: 0
Study 14715050 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11409662 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical activity advice at baseline and at 3, 6, and 12 months follow-up
Number of subjects: 69
Study 11409662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 69
Study 11409662 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical activity advice
Number of subjects: 69
Study 9861221 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1680
Study 9861221 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 1680
Study 9861221 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SSRIs and TCAs
Number of subjects: 1680
Study 7809416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular field of view (R‐FOV)
Number of subjects: 0
Study 7809416 — intervention group
Group type: COMPARATOR
Intervention: Square field of view (S‐FOV)
Number of subjects: 0
Study 3288683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg, three doses over 14 hours)
Number of subjects: 6
Study 3288683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3288683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (200 ng intradermal PAF)
Number of subjects: 6
Study 3288683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 6
Study 31036048 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) plus intranasal medication
Number of subjects: 600
Study 31036048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg) plus intranasal medication
Number of subjects: 600
Study 31036048 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus intranasal medication
Number of subjects: 600
Study 29110703 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Coaching (n = 201)
Number of subjects: 412
Study 29110703 — intervention group
Group type: COMPARATOR
Intervention: Low intensity control (n = 211)
Number of subjects: 412
Study 25755233 — intervention group
Group type: EXPERIMENTAL
Intervention: MyAsthma portal
Number of subjects: 60
Study 25755233 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 23180584 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-hyperoxia (HeHOx)
Number of subjects: 24
Study 21988668 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week titration (weekly quarter-dose increments over 3 weeks to full dose [30 µg])
Number of subjects: 234
Study 21988668 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week titration (biweekly quarter-dose increments over 6 weeks to full dose)
Number of subjects: 234
Study 21988668 — intervention group
Group type: COMPARATOR
Intervention: No titration (full dose over 8 weeks)
Number of subjects: 234
Study 18932010 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal Doppler monitoring (TDM)
Number of subjects: 127
Study 16532500 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m2 intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks)
Number of subjects: 170
Study 16532500 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 170
Study 16532500 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 170
Study 12684288 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled fluticasone (880 micro g/d) for 28 days
Number of subjects: 45
Study 12684288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14727967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 9689201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens 0.625 mg/day for 21 days plus chlormadinone 2 mg for the last 12 days (Group I)
Number of subjects: 27
Study 9689201 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated estrogens 0.625 mg/day plus chlormadinone 1 mg/day, continuous and uninterrupted (Group II)
Number of subjects: 27
Study 8126242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser only
Number of subjects: 28
Study 8126242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser followed by root planning
Number of subjects: 28
Study 8126242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser followed by air‐powder abrasive treatment
Number of subjects: 28
Study 8126242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 2671559 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rifampicin (600 mg), ethionamide (500 mg), and dapsone (100 mg) or clofazimine (100 mg) for 8 weeks followed by once weekly rifampicin (600 mg) and daily ethionamide (500 mg) and dapsone (100 mg) or clofazimine (100 mg) for 44 weeks
Number of subjects: 216
Study 791442 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (2,500,000 IU intravenous infusion over 24 hours)
Number of subjects: 595
Study 791442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no streptokinase)
Number of subjects: 595
Study 791442 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 595
Study 791442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 595
Study 791442 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase and Control group
Number of subjects: 595
Study 31665326 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at 67 µg/kg/day for 1 year
Number of subjects: 101
Study 31665326 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 101
Study 30676466 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-targeted and mediated video intervention
Number of subjects: 100
Study 30676466 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study 28323541 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak 3D (W3D)
Number of subjects: 105
Study 28323541 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong 3D (S3D)
Number of subjects: 105
Study 28323541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no 3D technology)
Number of subjects: 105
Study 28323541 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D technology (W3D and S3D)
Number of subjects: 105
Study 25398590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin-sealant-delivered cisplatin chemotherapy (FS)
Number of subjects: 42
Study 25398590 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin hyperthermic intraperitoneal perfusion chemotherapy (CHIC)
Number of subjects: 42
Study 23664200 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and micronutrients (sprinkles)
Number of subjects: 143
Study 23664200 — intervention group
Group type: COMPARATOR
Intervention: Micronutrients without zinc (control)
Number of subjects: 143
Study 21146267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (3 educational seminars, assistance with action plans, monthly monitoring)
Number of subjects: 77
Study 21146267 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (feedback report, educational materials)
Number of subjects: 77
Study 18040728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 32
Study 18040728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 32
Study 18040728 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (III)
Number of subjects: 32
Study 18040728 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (IV)
Number of subjects: 32
Study 17050042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer varicella vaccine (PUVV) - approximately 50,000 PFU
Number of subjects: 1366
Study 17050042 — intervention group
Group type: COMPARATOR
Intervention: Lower-titer formulation of VARIVAX - approximately 5400 PFU
Number of subjects: 1366
Study 17050042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer varicella vaccine (PUVV)
Number of subjects: 1366
Study 12624290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentrations of IL-10 (<6 pg/mL)
Number of subjects: 231
Study 12624290 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 levels
Number of subjects: 231
Study 12624290 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 levels
Number of subjects: 231
Study 12624290 — intervention group
Group type: EXPERIMENTAL
Intervention: Early worsening
Number of subjects: 231
Study 12624290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological worsening
Number of subjects: 231
Study 12624290 — intervention group
Group type: EXPERIMENTAL
Intervention: Eighty-three patients (35.9%)
Number of subjects: 231
Study 11008922 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU of retinol daily
Number of subjects: 2297
Study 11008922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297
Study 11008922 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 2297
Study 9081107 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (11.4 gm)
Number of subjects: 33
Study 9081107 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin solution (225 IU insulin, glucose with glucose clamp technique, and potassium) in addition to amino acid infusion
Number of subjects: 33
Study 9081107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 8382132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (7.5 mg)
Number of subjects: 22
Study 8382132 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat (1.25 mg)
Number of subjects: 22
Study 31384411 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (5 g of flaxseed oil containing 2.5 g α‐Linolenic acid)
Number of subjects: 44
Study 31384411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 ml of 1.5% fat milk)
Number of subjects: 44
Study 30258212 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus zoledronic acid
Number of subjects: 60
Study 30258212 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 60
Study 27158914 — intervention group
Group type: EXPERIMENTAL
Intervention: B-SAFE intervention
Number of subjects: 615
Study 27158914 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 615
Study 24595547 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID
Number of subjects: 504
Study 24595547 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 504
Study 24595547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 22471362 — intervention group
Group type: EXPERIMENTAL
Intervention: Keishi-bukuryo-gan (3.75g twice daily for seven days)
Number of subjects: 31
Study 22471362 — intervention group
Group type: EXPERIMENTAL
Intervention: Keishi-bukuryo-gan
Number of subjects: 31
Study 20860913 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg every 4 weeks
Number of subjects: 0
Study 20860913 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 4 weeks
Number of subjects: 0
Study 20860913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18569471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol 25 microm 4‐hourly
Number of subjects: 100
Study 18569471 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone 0.5 mg 12 hourly
Number of subjects: 100
Study 15799717 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (80 mg of caffeine)
Number of subjects: 17
Study 15799717 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (< 2 mg of caffeine)
Number of subjects: 17
Study 12447087 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-feedback treatment for lower paretic limb
Number of subjects: 25
Study 12447087 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-feedback treatment for upper paretic limb
Number of subjects: 25
Study 12447087 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated paretic limb of each group)
Number of subjects: 25
Study 10351968 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with EF <50%
Number of subjects: 30
Study 10351968 — intervention group
Group type: COMPARATOR
Intervention: Patients with EF >50%
Number of subjects: 30
Study 10351968 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with EF <50% (n=3)
Number of subjects: 30